Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of
early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial.
J Clin Oncol 2005;23(22):5138-47. Abstract
Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane
after two to three years of tamoxifen therapy in postmenopausal women with
primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women
after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract
Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen,
Alone or in Combination) trial after completion of 5 years’ adjuvant treatment
for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Jakesz R, on behalf of the ABCSG. Benefits of switching postmenopausal women with
hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen:
Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the
ARNO 95 Trial. Presentation. San Antonio Breast Cancer Symposium 2004;Abstract 2.
Thürlimann B et al. BIG 1-98: Randomized double-blind phase III study to evaluate
letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal
women with receptor-positive breast cancer. Proc ASCO 2005;Abstract 511. |
